Travere Therapeutics (TVTX) 10-Q2014 Q2 Quarterly report

Filed: 14 Aug 14, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: Adding, al, alleged, American, antitrust, approach, asserted, attention, Bank, bankruptcy, begun, borrowing, bound, California, Canada, Canadian, capacity, case, Chun, Clinuvel, colic, collateral, competing, complement, contravention, core, create, customary, CV, cysteine, cystine, cystinuria, damage, default, DEFICITFOR, departure, detrimental, difficult, disadvantage, discourage, disposing, dissolution, distinct, distract, distributor, diversion, dividend, eleven, encounter, encourage, enhance, EPS, equivalent, established, exacerbate, exploring, face, facility, final, flexibility, Food, fraud, function, fundamental, George, grow, growing, grown, guarantee, guaranteed, guarantor, guideline, half, healthcare, Huang, incorrect, indenture, infrastructure, insolvency, intensify, Jackson, junior, key, lack, LIBOR, line, mandatory, manner, misled, misrepresentation, Mission, negligent, notice, November, numerator, optimal, ordinary, owed, pain, passage, path, Pharmacal, plaintiff, pose, predict, premised, premium, prepayment, prevailing, prevalence, principle, proceeding, promised, promote, proper, punctual, pursue, rank, reconciliation, redeem, redefining, refinance, reorganization, restructure, retrospective, royalty, satisfaction, Schwab, seize, semiannually, senior, set, South, spent, stone, strain, Su, sublease, subordinated, subordination, SUBSIDIARIESCONDENSED, successful, supersede, targeted, Thiola, tipronin, transport, Trustee, unamortized, unexpected, uniform, unlimited, unsecured, valid, viability, voluntary, vulnerability, waived, winding, wrongfully, Yi

Removed: autism, aware, begin, Bulletin, determine, dystrophin, evaluate, history, impairment, investigation, liquidated, missing, original, protein, rata, recent, recombinant, recoverable, SAB, stage, threatened, trading, transferability, understand, underway, utrophin, vivo

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

TVTX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION OF

CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report on Form 10-Q of Retrophin, Inc. (the “Company”), for the period ending June 30, 2014 (the “Report”), the undersigned officer of the Company hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to such officer’s knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report, fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 13, 2014		/s/ Martin Shkreli
		Martin Shkreli Chief Executive Officer (Principal Executive Officer)